Pathology of fatty liver disease
- PMID: 17486051
- DOI: 10.1038/modpathol.3800680
Pathology of fatty liver disease
Abstract
Fatty liver disease is currently recognized as a common cause of liver test elevation, paralleling the worldwide 'epidemic' of obesity in adults and children. In many clinical practices, there is recognition that liver biopsy evaluation is the only means of diagnosis (or exclusion) of fatty liver disease, as neither laboratory tests nor imaging studies to date can provide complete data related to amount of steatosis, inflammation, liver cell injury, fibrosis, and architectural remodeling. Liver biopsy evaluation also provides a means of 'grading and staging' the lesions of fatty liver disease and of detecting clinically unsuspected processes. Liver biopsy evaluation is often the primary end point in clinical trials of treatment, thus, standardization of diagnosis and methods of grading and staging have become important. In this review, these concepts as well as the pathophysiologic bases for them are discussed.
Similar articles
-
Pathology of nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol. 2010 Apr;7(4):195-203. doi: 10.1038/nrgastro.2010.21. Epub 2010 Mar 2. Nat Rev Gastroenterol Hepatol. 2010. PMID: 20195271 Review.
-
Nonalcoholic fatty liver disease: is all the fat bad?Intern Med J. 2004 Apr;34(4):187-91. doi: 10.1111/j.1444-0903.2004.00574.x. Intern Med J. 2004. PMID: 15086699 Review.
-
Histopathology of nonalcoholic fatty liver disease.World J Gastroenterol. 2010 Nov 14;16(42):5286-96. doi: 10.3748/wjg.v16.i42.5286. World J Gastroenterol. 2010. PMID: 21072891 Free PMC article. Review.
-
Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis.Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1449-57. doi: 10.1097/MEG.0b013e32833f14a1. Eur J Gastroenterol Hepatol. 2010. PMID: 21389796
-
Pathology of nonalcoholic steatohepatitis.Hepatol Res. 2005 Oct;33(2):68-71. doi: 10.1016/j.hepres.2005.09.006. Epub 2005 Oct 7. Hepatol Res. 2005. PMID: 16214395
Cited by
-
Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses.FASEB J. 2016 Dec;30(12):4071-4082. doi: 10.1096/fj.201600427R. Epub 2016 Aug 23. FASEB J. 2016. PMID: 27553225 Free PMC article.
-
Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3.Hepatol Commun. 2022 Oct;6(10):2676-2688. doi: 10.1002/hep4.2035. Epub 2022 Aug 3. Hepatol Commun. 2022. PMID: 35923109 Free PMC article.
-
Effects of a diet rich in n-3 polyunsaturated fatty acids on hepatic lipogenesis and beta-oxidation in mice.Lipids. 2014 May;49(5):431-44. doi: 10.1007/s11745-014-3892-9. Epub 2014 Mar 14. Lipids. 2014. PMID: 24627299
-
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study.Hepatology. 2009 Oct;50(4):1113-20. doi: 10.1002/hep.23133. Hepatology. 2009. PMID: 19637190 Free PMC article.
-
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Cochrane Database Syst Rev. 2013 Dec 27;2013(12):CD008623. doi: 10.1002/14651858.CD008623.pub2. Cochrane Database Syst Rev. 2013. PMID: 24374462 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources